Home
News
Create
Screeners
Insights
Mahamaya Lifesciences
173.
00
+1.00
(+0.58%)
Market Cap
₹404.94 Cr
PE Ratio
31.10
Industry
Chemicals
Buy
Sell
Company Performance:
1D
+0.58%
1M
-0.46%
6M
+48.05%
1Y
+49.14%
5Y
+49.14%
View Company Insights
Latest news about Mahamaya Lifesciences
Mahamaya board to meet on May 25 to consider FY26 results
4 hrs ago
Yesterday
Mahamaya Lifesciences Limited will hold a board meeting on May 25, 2026, to approve audited standalone and consolidated financial results for the year ended March 31, 2026. The trading window remains closed until 48 hours post-results declaration.
Mahamaya Lifesciences Limited Exempt from Corporate Governance Compliance Due to BSE SME Listing
Apr 15, 2026
Mahamaya Lifesciences Files Quarterly Compliance Certificate for Q4FY26 Under SEBI Regulations
Apr 04, 2026
Mahamaya Lifesciences Confirms No Share Encumbrance by Promoters in FY26
Apr 03, 2026
Mahamaya Lifesciences Extends IPO Proceeds Utilisation Timeline to March 2028
Mar 10, 2026
More news about Mahamaya Lifesciences
09
Mar 26
Mahamaya Lifesciences Withdraws from Arihant Capital Virtual Conference Due to Scheduling Constraints
Mahamaya Lifesciences Limited has withdrawn from the Arihant Capital Bharat Connect Virtual Conference Rising Star 2026 scheduled for March 9, 2026, due to internal scheduling constraints and business priorities. The company communicated this decision to the Bombay Stock Exchange under SEBI regulations, reversing its earlier commitment made on March 5, 2026. Managing Director Krishnamurthy Ganesan signed the official withdrawal notification to maintain regulatory compliance and transparency with stakeholders.
22
Jan 26
Mahamaya Lifesciences Limited Receives 'Company of the Year – Medium Scale' Award at ICSCE 2026, Dubai
Mahamaya Lifesciences Limited received the 'Company of the Year – Medium Scale' award at ICSCE 2026 in Dubai on January 20, 2026, presented by PMFAI. The company disclosed this achievement under SEBI Regulation 30 on January 22, 2026, highlighting its excellence in the pharmaceutical sector and compliance with regulatory requirements.
17
Dec 25
Vijay Kedia Acquires 8.91 Lakh Shares in Mahamaya Lifesciences at ₹140 Per Share
Investor Vijay Kedia has purchased 8.91 lakh shares of Mahamaya Lifesciences, an SME-listed agro chemicals company, at ₹140 per share. The total investment amounts to ₹12.47 crores, representing a substantial stake in the small-cap firm. This move has drawn attention to the company and the agro chemicals sector.
02
Dec 25
Mahamaya Lifesciences Reports 17.6% Profit Growth in H1 FY26
Mahamaya Lifesciences, a provider of agricultural crop protection solutions, announced unaudited financial results for H1 FY26. Revenue from operations increased by 11.5% to ₹16,306.37 lakhs. Standalone profit rose by 17.6% to ₹852.56 lakhs. Earnings per share improved by 7.1% to ₹4.80. The results were approved by the Board of Directors on December 02, 2025. The company's performance indicates strong market position and increasing demand for its products in the agricultural sector.
Mahamaya Lifesciences
173.
00
+
1.
00
(+
0.
58
%)
1 Year Returns:
+49.14%
Industry Peers
UPL
634.35
(+
0.
17
%)
PI Industries
2,901.20
(-
7.
15
%)
Sumitomo Chemical
460.75
(-
1.
74
%)
Bayer Crop Science
4,315.50
(-
0.
89
%)
Sharda Cropchem
890.20
(-
2.
85
%)
Dhanuka Agritech
1,150.80
(-
2.
61
%)
Rallis
247.90
(-
2.
05
%)
NACL Industries
161.71
(-
0.
44
%)
Bhagiradha Chemicals & Industries
249.70
(+
0.
18
%)
Bharat Rasayan
1,395.70
(-
1.
32
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO